Sulpiride and risperidone treatment significantly improved the abnormal involuntary movements of two patients with Huntington’s disease on both actometer and clinical assessments. However, treatment with risperidone, but not sulpiride, significantly improved the functional activities as assessed by the Functional Disability Scale. To the best of our knowledge this is the first report of the successful treatment of Huntington’s disease with risperidone. Key words: Huntington’s disease; risperidone; sulpiride; actometer; AIMs; functional disability; case repor
Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves...
An international, multicenter, double-blind study was conducted in 183 patients with a first psychot...
A double-blind, placebo-controlled, crossover trial was carried out in 29patients with Huntington's ...
Abstract. To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington’s...
The aim of this review is to overview the pharmacological features of neuroleptics experienced in th...
Objectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsy...
Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce sch...
Objectives - To establish the effect of the atypical neuroleptic clozapine on chorea, voluntary moto...
Oral antipsychotics are used to treat motor and behavioural disturbances in Huntington’s disease (HD...
Preclinical data have shown that rilmenidine can regulate autophagy in models of Huntington's diseas...
PURPOSE: Huntington's disease is a rare condition. Patients are commonly treated with antipsychotics...
BACKGROUND: Whereas the treatment of motor symptoms in Huntington's disease (HD) receives much atten...
Atypical antipsychotics can alleviate the severity of tardive dyskinesia, but few studies have monit...
International audienceOBJECTIVE: Evidence-based medicine is a difficult goal to achieve in rare dise...
Purpose: To highlight the impact of caryolanemagnolol on gait measures in forward walking, balance a...
Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves...
An international, multicenter, double-blind study was conducted in 183 patients with a first psychot...
A double-blind, placebo-controlled, crossover trial was carried out in 29patients with Huntington's ...
Abstract. To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington’s...
The aim of this review is to overview the pharmacological features of neuroleptics experienced in th...
Objectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsy...
Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce sch...
Objectives - To establish the effect of the atypical neuroleptic clozapine on chorea, voluntary moto...
Oral antipsychotics are used to treat motor and behavioural disturbances in Huntington’s disease (HD...
Preclinical data have shown that rilmenidine can regulate autophagy in models of Huntington's diseas...
PURPOSE: Huntington's disease is a rare condition. Patients are commonly treated with antipsychotics...
BACKGROUND: Whereas the treatment of motor symptoms in Huntington's disease (HD) receives much atten...
Atypical antipsychotics can alleviate the severity of tardive dyskinesia, but few studies have monit...
International audienceOBJECTIVE: Evidence-based medicine is a difficult goal to achieve in rare dise...
Purpose: To highlight the impact of caryolanemagnolol on gait measures in forward walking, balance a...
Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves...
An international, multicenter, double-blind study was conducted in 183 patients with a first psychot...
A double-blind, placebo-controlled, crossover trial was carried out in 29patients with Huntington's ...